{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06093451",
            "orgStudyIdInfo": {
                "id": "30561"
            },
            "organization": {
                "fullName": "Temple University",
                "class": "OTHER"
            },
            "briefTitle": "Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder",
            "officialTitle": "An Open-Label, Randomized, Active Controlled Inpatient Trial Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder",
            "therapeuticArea": [
                "Mental Health",
                "Other"
            ],
            "study": "evaluating-sublingual-dexmedetomidine-for-moderate-to-severe-agitation-in-inpatients-with-schizophrenia-or-bipolar-disorder"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-07-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-07-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-05",
            "studyFirstSubmitQcDate": "2023-10-16",
            "studyFirstPostDateStruct": {
                "date": "2023-10-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-16",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Justin Faden",
                "investigatorTitle": "Associate Professor of Psychiatry",
                "investigatorAffiliation": "Temple University"
            },
            "leadSponsor": {
                "name": "Temple University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "BioXcel Therapeutics Inc",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "An open-label, randomized, active control inpatient trial to evaluate the efficacy and tolerability of sublingual dexmedetomidine for the treatment of agitation in inpatients with schizophrenia or bipolar disorder as measured by the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) and Agitation-Calmness Evaluation Scale (ACES). Lorazepam will serve as the active control.",
            "detailedDescription": "This is an open-label, randomized control trial where patients (N=32) with schizophrenia or bipolar disorder are randomized to receive either sublingual dexmedetomidine or oral lorazepam monotherapy for the treatment of episodic agitation. For moderate agitation (PANSS-EC score \u226514 and \\<20), patients will receive either sublingual dexmedetomidine 120mcg or oral lorazepam 2mg. For severe agitation (PANSS-EC \u226520), patients will receive either sublingual dexmedetomidine 180mcg or oral lorazepam 2mg. The PANSS-EC and ACES will be evaluated at baseline and after 15, 30, 60, and 120 minutes."
        },
        "conditionsModule": {
            "conditions": [
                "Schizophrenia Agitation",
                "Schizo Affective Disorder",
                "Bipolar Disorder",
                "Dexmedetomidine"
            ],
            "keywords": [
                "Agitation",
                "Schizophrenia",
                "Schizoaffective Disorder",
                "Bipolar Disorder"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 32,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dexmedetomidine",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with moderate agitation will receive sublingual dexmedetomidine 120 mcg as needed. Participants with severe agitation will receive dexmedetomidine 180 mcg as needed.",
                    "interventionNames": [
                        "Drug: Dexmedetomidine"
                    ]
                },
                {
                    "label": "Lorazapem",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Participants with moderate agitation will receive oral lorazapam 2 mgas needed. Participants with severe agitation will receive oral lorazapam 2 mg as needed.",
                    "interventionNames": [
                        "Drug: Lorazepam 2 MG/ML"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Dexmedetomidine",
                    "description": "Moderate agitation: 120 mcg Severe agitation: 180 mcg",
                    "armGroupLabels": [
                        "Dexmedetomidine"
                    ],
                    "otherNames": [
                        "Igalmi"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Lorazepam 2 MG/ML",
                    "description": "2 mg",
                    "armGroupLabels": [
                        "Lorazapem"
                    ],
                    "otherNames": [
                        "Ativan"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in PANSS-EC score at 120 minutes after medication administration",
                    "description": "Severity of agitation will be determined by administering the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC). Moderate to severe agitation will be defined as a PANSS-EC score \\>=14 and \\<20; and \\>= 20 is severe agitation.",
                    "timeFrame": "Baseline and at 120 minutes"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change from baseline in ACES score at 15, 30, 60, 90, and 120 minutes, or prior to receipt of any rescue medication for agitation.",
                    "description": "Severity of agitation will be measured using the standardized Agitation-Calmness Evaluation Scale. The 9-point scale indicated the degree of agitation as follows: 1=marked agitation, 4=normal behavior, 7 = marked calmness, 9=unarousable.",
                    "timeFrame": "Baseline and 15, 30, 60, 90, and 120 minutes"
                },
                {
                    "measure": "Change in PANSS-EC score at 15, 30, 60, and 90 minutes, or prior to receipt of any rescue medication for agitation.",
                    "description": "Severity of agitation will be determined by administering the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC). Moderate to severe agitation will be defined as a PANSS-EC score \\>=14 and \\<20; and \\>= 20 is severe agitation.",
                    "timeFrame": "Baseline and 15, 30, 60, and 90 minutes"
                },
                {
                    "measure": "Patient tolerability assessed by adverse events of dexmedetomidine",
                    "description": "Tolerability and safety of sublingual dexmedetomidine was assessed by evaluating spontaneously-reported adverse events. Treatment tolerability as assessed by adverse events will be tabulated by toxicity grade and organ systems as well as overall.",
                    "timeFrame": "Baseline through 120 minutes after medication administration"
                },
                {
                    "measure": "Patient satisfaction based on Medication Satisfaction Questionnaire (MSQ)",
                    "description": "Medication Satisfaction Questionnaire (MSQ) will be given to the subject to assess their satisfaction of their agitation medication two hours after initial medication administration. The Medication Satisfaction Questionnaire is a 7-point scale, with 1 being \"Extremely Dissatisfied\", 4 being \"Neither Satisfied or Dissatisfied\", and 7 being \"Extremely Satisfied\"",
                    "timeFrame": "Administered 120 minutes after medication administration"
                },
                {
                    "measure": "Assess the need for rescue medication for agitation within two hours of medication administration",
                    "description": "Need for rescue medication of sublingual dexmedetomidine will be assessed by reviewing the Medication Administration Reconciliation (MAR) available on the electronic medical record system for the two hour period of time following medication administration.",
                    "timeFrame": "Baseline and 2 hours after medication administration"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* The participant is an adult between the ages of 18-55 at the time of study participation\n* Hospitalized on an inpatient unit at Episcopal Hospital\n* Meet the DSM-5 criteria for schizophrenia, schizoaffective disorder, or bipolar disorder, as determined by routine clinical assessment conducted upon admission.\n* Are able to understand and read English\n* Are able to provide informed consent\n* Experiencing a moderate (PANSS-EC score \u226514 and \\<20) or severe (PANSS-EC score \u226520) episode of agitation\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding\n* Prisoners\n* Participant has an allergy to dexmedetomidine or lorazepam\n* Participant has mild, moderate or severe hepatic impairment\n* Participant has active pulmonary disease and is receiving treatment (oxygen, inhalers)\n* Individual is currently prescribed scheduled benzodiazepines or methadone\n* Participant history of QTc \u2265 500 msec or a history of arrythmia\n* Participant recent (within the last 2 days) fall, syncope (passing out), feeling lightheaded, or pulse \\<50.\n* Individual has a history of hypokalemia or hypomagnesemia within the past 2 years?\n* Participant is receiving high-risk medications, including:\n\n  1. Methadone\n  2. Midazolam\n  3. Opioids\n  4. High risk medications associated with the QT interval prolongation (sertindole, chlorpromazine, ziprasidone), (amiodarone, iboga, quinine, arsenic, ibutilide, selpercatinib, ivosidenib, bedaquiline, lenvatinib, sotalol, levoketoconazole, cisapride, vendetanib, mobocertinib, disopyramide, papaverine)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "55 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Justin Faden, DO",
                    "role": "CONTACT",
                    "phone": "2157070401",
                    "email": "Justin.Faden@tuhs.temple.edu"
                },
                {
                    "name": "Meghan Musselman, MD",
                    "role": "CONTACT",
                    "phone": "2157078483",
                    "email": "Meghan.Musselman@tuhs.temple.edu"
                }
            ],
            "locations": [
                {
                    "facility": "Temple University Episcopal Hospital",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19125",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "27857778",
                    "type": "BACKGROUND",
                    "citation": "San L, Marksteiner J, Zwanzger P, Figuero MA, Romero FT, Kyropoulos G, Peixoto AB, Chirita R, Boldeanu A. State of Acute Agitation at Psychiatric Emergencies in Europe: The STAGE Study. Clin Pract Epidemiol Ment Health. 2016 Oct 27;12:75-86. doi: 10.2174/1745017901612010075. eCollection 2016."
                },
                {
                    "pmid": "26234333",
                    "type": "BACKGROUND",
                    "citation": "Cots F, Chiarello P, Perez V, Gracia A, Becerra V. Hospital Costs Associated With Agitation in the Acute Care Setting. Psychiatr Serv. 2016 Jan;67(1):124-7. doi: 10.1176/appi.ps.201400508. Epub 2015 Aug 3."
                },
                {
                    "pmid": "25881240",
                    "type": "BACKGROUND",
                    "citation": "Rubio-Valera M, Luciano JV, Ortiz JM, Salvador-Carulla L, Gracia A, Serrano-Blanco A. Health service use and costs associated with aggressiveness or agitation and containment in adult psychiatric care: a systematic review of the evidence. BMC Psychiatry. 2015 Mar 4;15:35. doi: 10.1186/s12888-015-0417-x."
                },
                {
                    "pmid": "22461917",
                    "type": "BACKGROUND",
                    "citation": "Richmond JS, Berlin JS, Fishkind AB, Holloman GH Jr, Zeller SL, Wilson MP, Rifai MA, Ng AT. Verbal De-escalation of the Agitated Patient: Consensus Statement of the American Association for Emergency Psychiatry Project BETA De-escalation Workgroup. West J Emerg Med. 2012 Feb;13(1):17-25. doi: 10.5811/westjem.2011.9.6864."
                },
                {
                    "pmid": "22461918",
                    "type": "BACKGROUND",
                    "citation": "Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup. West J Emerg Med. 2012 Feb;13(1):26-34. doi: 10.5811/westjem.2011.9.6866."
                },
                {
                    "pmid": "26973742",
                    "type": "BACKGROUND",
                    "citation": "Zeller SL, Citrome L. Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting. West J Emerg Med. 2016 Mar;17(2):165-72. doi: 10.5811/westjem.2015.12.28763. Epub 2016 Mar 2."
                },
                {
                    "pmid": "35191924",
                    "type": "BACKGROUND",
                    "citation": "Preskorn SH, Zeller S, Citrome L, Finman J, Goldberg JF, Fava M, Kakar R, De Vivo M, Yocca FD, Risinger R. Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial. JAMA. 2022 Feb 22;327(8):727-736. doi: 10.1001/jama.2022.0799."
                },
                {
                    "pmid": "36198061",
                    "type": "BACKGROUND",
                    "citation": "Citrome L, Preskorn SH, Lauriello J, Krystal JH, Kakar R, Finman J, De Vivo M, Yocca FD, Risinger R, Rajachandran L. Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial. J Clin Psychiatry. 2022 Oct 3;83(6):22m14447. doi: 10.4088/JCP.22m14447."
                },
                {
                    "type": "BACKGROUND",
                    "citation": "Igalmi [package insert]. BioXcel Therapeutics, Inc; 2022."
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011595",
                    "term": "Psychomotor Agitation"
                },
                {
                    "id": "D000012559",
                    "term": "Schizophrenia"
                },
                {
                    "id": "D000001714",
                    "term": "Bipolar Disorder"
                },
                {
                    "id": "D000019964",
                    "term": "Mood Disorders"
                },
                {
                    "id": "D000011618",
                    "term": "Psychotic Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019967",
                    "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000068105",
                    "term": "Bipolar and Related Disorders"
                },
                {
                    "id": "D000020820",
                    "term": "Dyskinesias"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000011596",
                    "term": "Psychomotor Disorders"
                },
                {
                    "id": "D000019954",
                    "term": "Neurobehavioral Manifestations"
                },
                {
                    "id": "D000096762",
                    "term": "Aberrant Motor Behavior in Dementia"
                },
                {
                    "id": "D000001526",
                    "term": "Behavioral Symptoms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15376",
                    "name": "Schizophrenia",
                    "asFound": "Schizophrenia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4996",
                    "name": "Bipolar Disorder",
                    "asFound": "Bipolar Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21835",
                    "name": "Mood Disorders",
                    "asFound": "Affective Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14452",
                    "name": "Psychomotor Agitation",
                    "asFound": "Agitation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "asFound": "Schizo Affective Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21838",
                    "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M226",
                    "name": "Bipolar and Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M22574",
                    "name": "Dyskinesias",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M14453",
                    "name": "Psychomotor Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21826",
                    "name": "Neurobehavioral Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M6904",
                    "name": "Dementia",
                    "relevance": "LOW"
                },
                {
                    "id": "M3259",
                    "name": "Aberrant Motor Behavior in Dementia",
                    "relevance": "LOW"
                },
                {
                    "id": "M4818",
                    "name": "Behavioral Symptoms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000020927",
                    "term": "Dexmedetomidine"
                },
                {
                    "id": "D000008140",
                    "term": "Lorazepam"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006993",
                    "term": "Hypnotics and Sedatives"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018712",
                    "term": "Analgesics, Non-Narcotic"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000058647",
                    "term": "Adrenergic alpha-2 Receptor Agonists"
                },
                {
                    "id": "D000000316",
                    "term": "Adrenergic alpha-Agonists"
                },
                {
                    "id": "D000000322",
                    "term": "Adrenergic Agonists"
                },
                {
                    "id": "D000018663",
                    "term": "Adrenergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000927",
                    "term": "Anticonvulsants"
                },
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000014151",
                    "term": "Anti-Anxiety Agents"
                },
                {
                    "id": "D000014149",
                    "term": "Tranquilizing Agents"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000018757",
                    "term": "GABA Modulators"
                },
                {
                    "id": "D000018682",
                    "term": "GABA Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M22662",
                    "name": "Dexmedetomidine",
                    "asFound": "Twice daily",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11140",
                    "name": "Lorazepam",
                    "asFound": "ICG",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11901",
                    "name": "Mitoguazone",
                    "relevance": "LOW"
                },
                {
                    "id": "M10043",
                    "name": "Hypnotics and Sedatives",
                    "relevance": "LOW"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M20786",
                    "name": "Analgesics, Non-Narcotic",
                    "relevance": "LOW"
                },
                {
                    "id": "M20746",
                    "name": "Adrenergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M3668",
                    "name": "Adrenergic alpha-Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M3673",
                    "name": "Adrenergic Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4246",
                    "name": "Anticonvulsants",
                    "relevance": "LOW"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M16905",
                    "name": "Anti-Anxiety Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M20827",
                    "name": "GABA Modulators",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AntiConv",
                    "name": "Anticonvulsants"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}